Asiantuntijamme ovat kirjoittaneet, osallistuneet ja antaneet näkemystä satoihin julkaisuihin.
Törmälehto SM, Martikainen JA, Väätäinen ST, et al. Use of Anti-Dementia Drugs in Relation to Change in Cognition, Behavior, and Functioning in Alzheimer’s Disease over a Three-Year Period. J Alzheimers Dis. 2015;48(4):1033-41.
Välimäki TH, Martikainen JA, Hallikainen IT, Väätäinen ST, et al. Depressed Spousal Caregivers Have Psychological Stress Unrelated to the Progression of Alzheimer Disease: A 3-Year Follow-Up Report. J Geriatr Psychiatry Neurology 2015;28(4):272-80.
Soini E, Hallinen T, et al. Cost-Utility of First-Line Actinic Keratosis Treatments in Finland. Adv Ther 2015;32(5):455-76.
Gilmartin JF, Väätäinen S, Törmälehto S, Bell JS, Lönnroos E, Salo L, Hallikainen I, Martikainen J, et al. Depressive symptoms are associated with analgesic use in people with Alzheimer’s disease. PLoS One 2015;10(2):e0117926.
Soini E, et al. Glycosylated haemoglobin (HbA1c) monitoring and lower HBA1c values can result to higher quality of life? Beta regression modelling. 15th Biennial SMDM European Meeting, Antwerpen. Program and abstracts 2014.
Heinonen J, Soini E, et al. Costs of episodes (COE): analysis based on ICPC-2 classification. 15th Biennial SMDM European Meeting, Antwerpen. Program and abstracts, 2014.
Asseburg, C. Det internationella Mount Hood-samarbetet. Tredje nationella hälsoekonomiska konferensen, Lund, Sweden, Mar 20-21, 2014.
Heinonen J, Koskela T, Soini E, et al. Terveyskeskuspotilaiden hoitoepisodit ja niiden kustannukset. Tampereen Lääkäripäivät XXXV, Mar 19-21, 2014.
Terveydenhuollon rahoituspäätökset – Millä perusteilla ne tehdään, mikä on kustannusvaikuttavuustiedon merkitys? Puheenjohtaja: Soini E.
Soini E, et al. Cost-Utility Analysis (CUA) of first-line Disease-Modifying Treatments (DMT) versus Best Supportive Care (BSC) in Finnish Relapsing-Remitting Multiple Sclerosis (RRMS) patients. Value in Health 2014;17:A399
Heinonen J, Soini E, et al. Episodes of care and their costs based on ICPC-2 classification: Three month follow-up study in Finland. Value Health 2014;17:A549.
Soini E, Hallinen T, et al. Cost-Utility Analysis (CUA) of first-line Actinic Keratosis (AK) treatments in Finland. Value Health 2014;17:A609.
Asseburg C. Current Challenges in the Health-Economic Modelling of Diabetes. Diabetes simulation models as prognostic tools. Medical University Vienna, Austria, September 15, 2014. Podium. https://healtheconomics.meduniwien.ac.at/fileadmin/healtheconomics/Documents/Diabetes_Programme_20140915.pdf
Asseburg C. Uncertainty in the Challenge 3. Mt Hood 7 Meeting on the Health-Economic Modelling of Diabetes. Stanford University, Palo Alto, CA, USA, June 18, 2014. Podium.
Soini E, et al. International normalized ratio (INR) monitoring and percent time in therapeutic INR range (TTR) can have impact on patient’s quality of life? Application of Beta regressions in a prospective 3 months setting. 15th Biennial SMDM European Meeting, Antwerpen. Program and abstracts 2014.
Välimäki T, Martikainen J, et al. Decreasing sense of coherence and its determinants in spousal caregivers of persons with mild Alzheimer’s disease in three year follow-up. Int Psychogeriatr 2014;26(7):1211-20.
Väätäinen S, Keinänen-Kiukaanniemi S, Saramies J, Uusitalo H, Tuomilehto J, Martikainen J. Quality of life along the diabetes continuum: a cross-sectional view of health-related quality of life and general health status in middle-aged and older Finns. Qual Life Res 2014;23(7):1935-44.
Hallinen T, Soini E, Asseburg, et al. Warfarin treatment among Finnish patients with atrial fibrillation: retrospective registry study based on primary health care data. BMJ Open 2014;4:e004071.
Aarnio E, Martikainen J, et al. Register-based predictors of adherence among new statin users in Finland. J Clin Lipidol 2014;8(1):117-25.
Väätäinen S & Martikainen J. Disutility associated with erectile dysfunction in the middle-aged or older males. Value in Health 2014;17(7):A514.
Soini E, Hallinen T, et al. Cost-utility of vortioxetine in the treatment of major depressive disorder: Comparison with agomelatine, bupropion, sertraline and venlafaxine in the Finnish Setting. Value in Health 2014;17:A459.
Soini E, et al. Modelling the persistence of Disease-Modifying drug Treatment (DMT) and its independent drivers in Finnish Multiple Sclerosis (MS) patients: Parametric survival modelling. Value in Health 2014;17:A400.
Tuomilehto H, et al. The impact of weight reduction in the prevention of the progression of obstructive sleep apnea: an explanatory analysis of a 5-year observational follow-up trial. Sleep Med 2014;15(3):329-35. Collaborators: Soini E, Martikainen J.
Martikainen J, Soini E, et al. Economic impact of 13-valent pneumococcal conjugate vaccine in Finnish adults >50 years with underlying chronic medical conditions. J EvalClin Pract 2014;20(4):333-41.
Asseburg C (ed). Economics, modelling and diabetes – The Mt. Hood Newsletter. ESiOR Oy, Kuopio, Finland.
Hallikainen I, Martikainen J, et al. The Progression of Alzheimer’s Disease Can Be Assessed with a Short Version of the CERAD Neuropsychological Battery. Dement Geriatr Cogn Dis Extra 2014;4(3):494-508.
Kangaspunta V, Koskela T, Soini E, et al. Potilaiden arvioon terveyskeskuskäynnin hyödystä vaikuttavat tekijät. Suom Lääkäril 2014;69(22):1654-1659c.
Soini E. Kustannusvaikuttavuus pienillä potilasryhmillä. Lääketietokeskus: Vaikuttavuusiltapäivä – kohti räätälöityjä lääkehoitoja. Helsinki: training. Oct 10, 2013.
Soini E. Productivity costs in Finnish cost-effectiveness assessments. KWRC seminar 27.5.2013.
Soini E. Reuman hoidon kustannusvaikuttavuus Suomessa. BestPractice Reumasairaudet – Lääketieteen asiantuntijoiden ammattilehti 2013;1(3):7-9.